Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Labs, Test Makers Urge Congress To Pass Diagnostic Reforms

Executive Summary

More than 80 industry, laboratory, health-care provider and patient groups sent a letter to two congressional committees, urging them to advance a bill to modernize the current way FDA regulates diagnostic tests, including possibly a new regulated product category that combines laboratory developed tests and in vitro diagnostics.


Related Content

Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm
Molecular Dx Exec Named New US FDA Diagnostics Chief
Guidance To Put More Combo Products Into Device Realm Due Out In Fall, FDA Commish Gottlieb Tells Congress
bioMérieux America CEO Talks Dx Reform Progress, Antibiotic Resistance
US And EU Systems For Personalized Medicine: Paths Diverging?
Medtech Execs Stomping The Hill On Device Tax, Diagnostics Reforms
House Panel Approves Boosts For FDA Digital Health Plan, Quality Medtech Manufacturing
FDA Pathway Options Are Growing For Diagnostics, FDA's Gottlieb Tells Commercial Labs
Diagnostics Reg Overhaul Floated In US House





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts